On November 15, the State Food and Drug Administration issued the Notice of the General Office of the General Administration of Customs of the State Food and Drug Administration on Matters Related to the Establishment of Shijiazhuang Air Port as a Drug Import Port, which showed that after approval, it was agreed to add Shijiazhuang Air Port as a drug import port
.
The announcement clarifies that from the date of issuance of this notice, in addition to the drugs specified in Article 10 of the Measures for the Administration of Drug Import (hereinafter referred to as the "Measures"), other imported Chinese medicines (excluding Chinese medicinal materials) and chemicals (including narcotic drugs and psychotropic substances) may be imported
through Shijiazhuang Air Port.
It has been learned that the drugs stipulated in Article 10 of the "Measures for the Administration of Drug Imports" include biological products, drugs sold in China for the first time, and other drugs
prescribed by the State Council.
The approval of Shijiazhuang drug import port means that Hebei Province has since ended the history of "only imported drugs, no drug imports", which will effectively shorten the drug import procurement cycle and reduce drug costs, alleviate the problems of expensive, slow and difficult imported drugs for the people, and promote the investment attraction of large pharmaceutical projects, further helping the construction of Shijiazhuang's "100 billion-level" biomedical industry cluster; At the same time, it is also conducive to reducing the workload
of customs clearance and inspection of drug imports in Beijing and Tianjin.
The biomedical industry is a strategic emerging industry in China, affected by the support of favorable policies, the increase of talents, capital entry and other factors, the industrial scale is huge and the market prospects are broad
.
Data show that the domestic biopharmaceutical market has reached about 387 billion yuan in 2020, and it is expected that this market size will grow to 1.
3 trillion yuan
by 2030.
In recent years, Shijiazhuang City is transforming from mainly low-end drugs such as APIs to high-end medicine, promoting the high-quality development of the pharmaceutical industry, and forming an industrial system
led by innovative drugs, fermented drugs as the lead, modern traditional Chinese medicine as the feature, genetic engineering drugs as the guide, and medical devices and pharmaceutical circulation services as supplements.
Data show that in the first half of this year, the added value of Shijiazhuang's pharmaceutical industry increased by 15.
4% year-on-year, 4.
3 percentage points higher than the added value of industries above designated size in the city, and became a strong engine
for driving the development of industrial economy.
Shijiazhuang has a strong foundation in biomedical industry, with 1,800 biomedical market entities
.
In 2021, the annual operating income of pharmaceutical enterprises above designated size in Shijiazhuang City has exceeded 60 billion yuan, and five major biomedical industry clusters have been formed: the biomedical industrial base of the high-tech zone, the biomedical industrial park of Shijiazhuang Economic Development Zone, the modern traditional Chinese medicine industrial park of Luancheng, the biological industrial park of Zhao County, and the Shenze biological industrial park, with supporting services
covering the fields of R&D-incubation-industrialization-pharmaceutical circulation.
In the context of the current rapid development momentum of the biomedical industry, Shijiazhuang City has also seized the opportunity, the city has proposed since 2021 to promote the two major industries of biomedicine and a new generation of electronic information to make breakthroughs, vigorously develop equipment manufacturing, modern food, trade and logistics industries, and make every effort to build more than 5 industrial clusters
of more than 100 billion yuan.
By the end of the "14th Five-Year Plan", the operating income of the city's two major industries of electronic information and biomedicine will reach 150 billion yuan, the operating income of commerce and logistics will reach 630 billion yuan, and the operating income of equipment manufacturing and modern food will reach 100 billion yuan
respectively.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
